Filing Flows › Sunshine Biopharma (SBFM) › Q4 2024
Sunshine Biopharma (SBFM) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Apr 1, 2025
Sunshine Biopharma (SBFM) reported revenue of $9.6M for the fourth quarter 2024 (Q4 2024), +25% from a year earlier and +14% from the quarter before. Operating margin was -21.2%, net loss $2.2M (22.5% of revenue).
Sunshine Biopharma, Q4 2024: revenue $9.6M (+25% year over year), operating margin -21.2%, net loss $2.2M, operating cash flow −$3.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.6M | +14% | +25% |
| Operating profit | −$2.0M | — | — |
| Net earnings | −$2.2M | — | — |
| Operating cash flow | −$3.4M | — | — |
What changed
Revenue was $9.6M in Q4 2024, up 25% year over year and up 14% from the previous quarter.
Gross margin was 32.2%, down 1.2 points from a year earlier. Operating costs exceeded revenue by $2.0M, an operating margin of -21.2%. Operating expenses grew 37% against revenue growth of 25%. The quarter ended with a net loss of $2.2M, wider than the previous quarter's $1.2M loss.
Operating cash flow was −$3.4M. Non-cash charges added back $65K of depreciation and amortization. Working capital and other items used $1.3M. Capital expenditures of $103K exceeded it, leaving free cash flow of −$3.5M.
Questions
What was Sunshine Biopharma's revenue in the fourth quarter 2024?
Sunshine Biopharma (SBFM) reported revenue of $9.6M for the fourth quarter 2024 (Q4 2024), +25% from a year earlier and +14% from the quarter before.
Was Sunshine Biopharma profitable in the fourth quarter 2024?
Operating loss was $2.0M (-21.2% of revenue) and net loss $2.2M.
Source: Sunshine Biopharma 10-K on SEC EDGAR.